News | September 26, 2024
Pfizer withdraws all lots of sickle cell disease treatment voxelotor
Pfizer's decision is based on the totality of clinical data
Pfizer's decision is based on the totality of clinical data
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
ALS patients experience neuroinflammation and rapid neurodegeneration
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Subscribe To Our Newsletter & Stay Updated
